Comparing two ways to give blinatumomab for newly diagnosed acute lymphoblastic leukaemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares two ways of giving blinatumomab (a drug that helps your immune system find and kill leukaemia cells): as a continuous intravenous (IV) infusion versus a simpler subcutaneous (under the skin) injection. It is for adults newly diagnosed with B-cell precursor ALL, and the goal is to see if the subcutaneous injection works just as well while being more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been recently diagnosed with a type of acute lymphoblastic leukaemia called B-cell precursor ALL, and you must not have already received chemotherapy for it (except for a few early doses into the spine or a short pre-phase).
- You must be 18 years old or older.
- You must be in reasonably good overall health — meaning your kidneys, liver, and heart are functioning well enough (for example, your heart's pumping ability is at least 50% and you don't have serious heart conditions).
- You must not have a serious brain or nervous system condition, such as epilepsy, seizures, stroke, severe brain injury, dementia, Parkinson's disease, or psychosis.
- You must not have another cancer that required treatment in the past 3 years, except for certain very early-stage cancers that were completely treated (like some skin, cervical, or breast cancers).
- You must not have an active or uncontrolled infection, including HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable drug called BLB101 compared to a standard treatment (Blincyto) for adults with a type of leukemia called B-ALL that has come back or not responded to treatment. It may help you if your leukemia has the CD19 protein and you have had 1 to 2 previous treatments.
This trial tests if a new drug, RDC-Blinatumomab, works better than the usual chemotherapy (hyperCVAD) for people with a type of leukemia called Ph-negative B-ALL. It is for newly diagnosed patients who haven't had other treatments yet.
This study tests a new treatment for adults newly diagnosed with a type of leukemia called B-ALL. It uses a lower dose of chemotherapy followed by a 14-day course of blinatumomab, which helps the immune system fight cancer cells. This approach may reduce side effects while still being effective.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This trial tests a combination of two drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective.
Hear when a new Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.